huge beat rais signific upsid
impress cgm market inflect point
dxcm revenu y/i came ahead street
estim impress upsid quarter old system
new system launch last week full launch
like catalyst next sever quarter strength
across board us commerci busi medicar
cite increas awar marketplac larger competitor educ
patient valu proposit use continu glucos monitor cgm
point recent survey initi see note think cgm penetr
inflect point multipl cgm player benefit expand market
major intens diabet patient still use fingerstick today continu
see upsid estim rais po new po base
prior po base revenu estim reiter buy rate
look number
rais full year guidanc y/i growth rang
y/i growth first half grew revenu guidanc
impli second half growth guidanc take account
deceler second half tougher comp guidanc also assum
headwind potenti lower revenu per patient could come new
payment distribut model subscript model commerci busi
access pharmaci channel guidanc continu look conserv us
given strength underli market launch opportun
growth outsid us
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim launch medicar
conserv assumpt util price
competit could drive upsid near term
long-term penetr non-intens type
increas total avail market opportun
also beleiv cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
valu share ev/sal basi given unprofit today price
object translat revenu estim multipl line
small mid-cap med-tech compani similar revenu growth rate
upsid risk strateg activ launch medicar ad patient
expect less impact expect competit faster approv
pipelin product downsid risk price pressur fewer patient
added/high attrit current patient due competitor threat lack patient
want adopt cgm delay pipelin product
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
